Insights from the CLEAR Outcomes trial on MASLD and heart health
At Julius Clinical, we are collaborating with Esperion to dive deeper into the findings of the CLEAR Outcomes trial. Our focus? Investigating the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular complications.
Our analysis highlights that elevated non-invasive tests for liver steatosis and fibrosis are strongly associated with a heightened risk of major adverse cardiovascular events (MACE). Importantly, the study also showed that bempedoic acid significantly reduces MACE risk, particularly in patients with high steatosis scores on non-invasive tests.
These findings underscore the potential of non-invasive liver tests to identify patients at the greatest risk for cardiovascular events. They also emphasize the importance of early cardiovascular management in patients with MASLD, offering a proactive approach to reducing risk and improving outcomes.
By bridging insights from liver and cardiovascular health, this analysis could pave the way for more targeted and effective interventions for high-risk patients.
Outcomes of the CLEAR study:
Related news
Metabolic dysfunction associated steatotic liver disease and the heart
Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...
GRIPonMASH received significant EU funding to improve prevention and care of Metabolic dysfunction-Associated SteatoHepatitis (MASH)
Utrecht, The Netherlands, 05-02-2024GRIPonMASH, a newly founded consortium consisting of 27 European institutions and companies, has bundled resources to bring about a transformational change in the detection and treatment of Metabolic Dysfunc...
64% of all surveyed physicians underestimated the prevalence of NAFLD (now designated as MASLD)
We are proud to announce the publication of our latest research article titled "A global survey of health care workers' awareness of nonâalcoholic fatty liver disease: The AwareNASH survey." This article summarizes the findings of the AwareNASH ...